Function determines structure in the vasculature: lessons from insulin resistance

Abstract

CALL FOR PAPERSMetabolic SyndromeFunction determines structure in the vasculature: lessons from insulin resistanceKieren Mather, and Subodh VermaKieren Mather, and Subodh VermaPublished Online:01 Aug 2005https://doi.org/10.1152/ajpregu.00297.2005MoreSectionsPDF (41 KB)Download PDF ToolsExport citationAdd to favoritesGet permissionsTrack citations vascular dysfunction has been well characterized in both human and experimental insulin resistance. Alterations in a range of features of vascular function have been described with insulin resistance (15, 18), including thickened resistance vessel walls with increased structural stiffness (23), reductions in capillary density (rarefaction) (4, 6), reductions in bioavailable nitric oxide (21), increased production of free radicals, augmented vasoconstrictor response to α-adrenergic agonists and to ANG II (3), and augmented production of and responsiveness to endothelin (16, 22, 24). As these features are all present concurrently, it has been difficult to dissect the individual contributions of specific metabolic factors to each component of vascular dysfunction. The broader set of features of the metabolic syndrome also accompany states of insulin resistance, in particular, elevations in blood pressure, further complicating in vivo studies of these relationships. These challenges have made for a body of literature that does not clearly answer the question of which factors are primary in the pathogenesis of vascular dysfunction in insulin resistance.Endothelial products are widely recognized to contribute to vascular health beyond the acute regulation of vascular function. A timely example of this is the known proatherosclerotic and proinflammatory effects of endothelin, which is mitogenic in addition to exerting acute effects on vascular tone. Nitric oxide has been widely noted to be antiatherosclerotic, but predominantly through antiplatelet effects rather than direct effects on smooth muscle cell proliferation (14). Angiogenesis, however, does appear to depend on the availability of nitric oxide (10). Mice genetically engineered to be deficient in endothelial nitric oxide synthase (eNOS) have a number of hemodynamic and metabolic abnormalities that suggest more than an acute regulatory role of nitric oxide (2, 11, 20), and also exhibit structural abnormalities in blood vessels, including capillary rarefaction (11). The strong association of these structural features with reductions in bioavailable nitric oxide have led to the testable hypothesis that the reductions in nitric oxide bioavailability are directly responsible for these observed structural changes.In this issue of the American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, Frisbee (4) has rigorously tested this hypothesis. Using a broad set of concurrent measurements of structure and function, studies were performed in leptin receptor-deficient obese Zucker rats (OZR) and their lean counterparts heterozygous for the mutation (LZR). Rats were treated for 4 wk with orally available agents added to their chow. The role of oxidative stress was addressed using Tempol, a superoxide dismutase mimetic, and the role of nitric oxide deficiency was addressed using NG-nitro-l-arginine methyl ester (l-NAME), a competitive antagonist of nitric oxide synthase. Some rats treated with l-NAME received hydralazine to restore blood pressure, allowing assessment of the independent effects of reduced nitric oxide bioavailability. The expected structural and functional deficits were observed in vessels from OZR, with evidence of increased oxidant stress, impaired basal and stimulated nitric oxide production, reduced microvessel density [histologically determined using a microvessel stain (5)], and altered structural features (reduced passive and active diameter, right-shifted stress/strain relationship, and reduced total distensibility). Antioxidant treatment in these animals with Tempol produced improvements in basal and stimulated nitric oxide production ex vivo and improved stimulated but not basal blood flow in vivo. This was accompanied by an improvement (but not normalization) in microvessel density but without improvement in structural features of resistance vessels. Concurrent treatment with Tempol and l-NAME prevented these improvements, while maintaining the suppression of oxidant stress, suggesting that these effects were attributable to increased nitric oxide bioavailability rather than a nonspecific effect of antioxidant therapy. In LZR, the functional alterations seen in OZR were recapitulated by 4 wk of l-NAME treatment. Although this was not accompanied by alterations in structural features of the vessels, a reduction in microvessel density was seen. These changes persisted when the rise in blood pressure that accompanies l-NAME therapy was prevented by concurrent treatment with hydralazine. In total, these findings argue that the changes in vasodilator function and microvascular density seen in OZR are attributable to impaired nitric oxide bioavailability and that oxidant stress contributes only indirectly via its effects on nitric oxide. The dissociation of these effects from the structural features suggests that other or additional factors are responsible for these changes or that the treatments were of insufficient duration to affect these parameters.Previously, other investigators have used a similar approach to address the question of the relative roles of nitric oxide bioavailability versus hypertension in the pathogenesis of microvascular rarefaction. In one report, the effect of NOS inhibition to induce rarefaction was partially reversible with spironolactone, enalapril, and verapamil (17). These findings suggested that the relevant effect was the induction of hypertension rather than a specific antagonism of NOS, but this study was less rigorous than the current paper by Frisbee in demonstrating whether the antihypertensive therapy used, in fact, altered the suppression of nitric oxide. In direct contrast to the current study, eNOS-deficient mice developed microvascular rarefaction concurrently with hypertension as they aged, and this phenomenon was prevented by concurrent hydralazine treatment (11). Thus, although the current findings by Frisbee are internally consistent, there is some conflict with studies from other authors regarding the relative contributions of hypertension per se versus nitric oxide deficiency in the loss of microvascular networks.In humans, the association of reduced capillary density with insulin resistance has been repeatedly demonstrated (8, 9, 13, 19). Further, an association of capillary density with impairments in insulin-induced vasodilation in elderly men has been reported (7), which more directly ties insulin’s nitric oxide-dependent vascular actions (25) to these structural changes. However, much remains to be done to better understand these interrelationships, specifically regarding the question of how therapies addressing vascular function or insulin sensitivity might alter these parameters, and what impact this might have on skeletal muscle function and metabolism.Does capillary rarefaction contribute to hypertension or insulin resistance independently of impairments in nitric oxide bioavailability? Mice deficient in eNOS have increased vascular resistance and capillary rarefaction, with separate contributions of each of these features to elevated blood pressure (12). We know that insulin signals through typical insulin receptor signaling pathways to eNOS (25) and that this action is impaired in parallel with impaired metabolic actions of insulin in states of insulin resistance. Observations that eNOS-deficient mice recapitulate not just insulin resistance but also other systemic features of insulin resistance (2, 20) suggest that this action of insulin is a key component of overall insulin action. In humans, coinfusion of NG-monomethyl-l-arginine with insulin acutely reduces insulin’s metabolic effects (1), on a timescale that is too short to involve structural changes. These observations suggest that vascular function (reflected in nitric oxide bioavailability) contributes importantly to overall insulin action. However, relatively little has been done in humans or in animal models of insulin resistance to explore the independent contributions of vascular dysfunction and structural alterations to metabolic status.The present paper suggests that nitric oxide bioavailability drives microvascular structure and that the adverse changes with insulin resistance can be reversed through therapy to reduce nitric oxide consumption by superoxide. More generally, this provides hope that the structural, as well as functional vascular abnormalities in insulin resistance, can be improved with therapies targeting the vasculature. These findings will ultimately be reflected in the treatment of hypertension, as well as the treatment of insulin-resistant states like the metabolic syndrome.REFERENCES1 Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, and Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest 96: 786–792, 1995.Crossref | PubMed | ISI | Google Scholar2 Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, Vollenweider P, Pedrazzini T, Nicod P, Thorens B, and Scherrer U. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 104: 342–345, 2001.Crossref | PubMed | ISI | Google Scholar3 Egan BM. Neurohumoral, hemodynamic, and microvascular changes as mechanisms of insulin resistance in hypertension: a provocative but partial picture. Int J Obes 15, Suppl 2: 133–139, 1991.PubMed | ISI | Google Scholar4 Frisbee JC. Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 289: R307–R316, 2005.Link | ISI | Google Scholar5 Greene AS, Lombard JH, Cowley AW Jr, and Hansen-Smith FM. Microvessel changes in hypertension measured by Griffonia simplicifolia I lectin. Hypertension 15: 779–783, 1990.Crossref | PubMed | ISI | Google Scholar6 Hedman A, Andersson PE, Reneland R, and Lithell HO. Insulin-mediated changes in leg blood flow are coupled to capillary density in skeletal muscle in healthy 70-year-old men. Metabolism 50: 1078–1082, 2001.Crossref | PubMed | ISI | Google Scholar7 Hedman A, Berglund L, Essen-Gustavsson B, Reneland R, and Lithell H. Relationships between muscle morphology and insulin sensitivity are improved after adjustment for intraindividual variability in 70-year-old men. Acta Physiol Scand 169: 125–132, 2000.Crossref | PubMed | Google Scholar8 Hedman A, Reneland R, and Lithell HO. Alterations in skeletal muscle morphology in glucose-tolerant elderly hypertensive men: relationship to development of hypertension and heart rate. J Hypertens 18: 559–565, 2000.Crossref | PubMed | ISI | Google Scholar9 Katz MA, McCuskey P, Beggs JL, Johnson PC, and Gaines JA. Relationships between microvascular function and capillary structure in diabetic and nondiabetic human skin. Diabetes 38: 1245–1250, 1989.Crossref | PubMed | ISI | Google Scholar10 Kiefer FN, Misteli H, Kalak N, Tschudin K, Fingerle J, Van der Kooij M, Stumm M, Sumanovski LT, Sieber CC, and Battegay EJ. Inhibition of NO biosynthesis, but not elevated blood pressure, reduces angiogenesis in rat models of secondary hypertension. Blood Press 11: 116–124, 2002.Crossref | PubMed | ISI | Google Scholar11 Kubis N, Besnard S, Silvestre JS, Feletou M, Huang PL, Levy BI, and Tedgui A. Decreased arteriolar density in endothelial nitric oxide synthase knockout mice is due to hypertension, not to the constitutive defect in endothelial nitric oxide synthase enzyme. J Hypertens 20: 273–280, 2002.Crossref | PubMed | ISI | Google Scholar12 Kubis N, Richer C, Domergue V, Giudicelli JF, and Levy BI. Role of microvascular rarefaction in the increased arterial pressure in mice lacking for the endothelial nitric oxide synthase gene (eNOS3pt−/−). J Hypertens 20: 1581–1587, 2002.Crossref | PubMed | ISI | Google Scholar13 Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, Yki-Jarvinen H, Christin L, Secomb TW, and Bogardus C. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest 80: 415–424, 1987.Crossref | PubMed | ISI | Google Scholar14 Luscher TF, Tanner FC, Tschudi MR, and Noll G. Endothelial dysfunction in coronary artery disease. Annu Rev Med 44: 395–418, 1993.Crossref | PubMed | ISI | Google Scholar15 Mather K, Anderson TJ, and Verma S. Insulin action in the vasculature: physiology and pathophysiology. J Vasc Res 38: 415–422, 2001.Crossref | PubMed | ISI | Google Scholar16 Mather K, Mirzamohammadi B, Lteif A, Steinberg H, and Baron A. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes mellitus. Diabetes 51: 3517–3523, 2002.Crossref | PubMed | ISI | Google Scholar17 Meirelles Pereira LM and Mandarim-de-Lacerda CA. Effect of antihypertensive drugs on the myocardial microvessels in rats with nitric oxide blockade. Pathol Res Pract 196: 305–311, 2000.Crossref | PubMed | ISI | Google Scholar18 Petrie JR, Ueda S, Webb DJ, Elliott HL, and Connell JM. Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation 93: 1331–1333, 1996.Crossref | PubMed | ISI | Google Scholar19 Serne EH, Stehouwer CD, ter Maaten JC, ter Wee PM, Rauwerda JA, Donker AJ, and Gans RO. Microvascular function relates to insulin sensitivity and blood pressure in normal subjects. Circulation 99: 896–902, 1999.Crossref | PubMed | ISI | Google Scholar20 Shankar RR, Wu Y, Shen HQ, Zhu JS, and Baron AD. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49: 684–687, 2000.Crossref | PubMed | ISI | Google Scholar21 Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, and Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97: 2601–2610, 1996.Crossref | PubMed | ISI | Google Scholar22 Verma S, Yao L, Stewart DJ, Dumont AS, Anderson TJ, and McNeill JH. Endothelin antagonism uncovers insulin-mediated vasorelaxation in vitro and in vivo. Hypertension 37: 328–333, 2001.Crossref | PubMed | ISI | Google Scholar23 Westerbacka J, Vehkavaara S, Bergholm R, Wilkinson I, Cockcroft J, and Yki-Jarvinen H. Marked resistance of the ability of insulin to decrease arterial stiffness characterizes human obesity. Diabetes 48: 821–827, 1999.Crossref | PubMed | ISI | Google Scholar24 Wu SQ, Hopfner RL, McNeill JR, Wilson TW, and Gopalakrishnan V. Altered paracrine effect of endothelin in blood vessels of the hyperinsulinemic, insulin-resistant obese Zucker rat. Cardiovasc Res 45: 994–1000, 2000.Crossref | PubMed | ISI | Google Scholar25 Zeng G, Nystrom FH, Ravichandran LV, Cong LN, Kirby M, Mostowski H, and Quon MJ. Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide in human vascular endothelial cells. Circulation 101: 1539–1545, 2000.Crossref | PubMed | ISI | Google ScholarAUTHOR NOTESAddress for reprint requests and other correspondence: K. Mather, Div. of Endocrinology and Metabolism, Indiana Univ. School of Medicine, 975 West Walnut St., IB424, Indianapolis IN 46202 (e-mail: [email protected]) Download PDF Previous Back to Top Next FiguresReferencesRelatedInformation Cited ByRenal blood flow and dynamic autoregulation in conscious miceRadu Iliescu, Radu Cazan, Gerald R. McLemore, Marcia Venegas-Pont, and Michael J. Ryan1 September 2008 | American Journal of Physiology-Renal Physiology, Vol. 295, No. 3An Integrated View of Insulin Resistance and Endothelial DysfunctionEndocrinology and Metabolism Clinics of North America, Vol. 37, No. 3Adverse renal consequences of obesityKaren A. Griffin, Holly Kramer, and Anil K. Bidani1 April 2008 | American Journal of Physiology-Renal Physiology, Vol. 294, No. 4Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertensionMiguel L. Graciano, Akira Nishiyama, Keith Jackson, Dale M. Seth, Rudy M. Ortiz, Minolfa C. Prieto-Carrasquero, Hiroyuki Kobori, and L. Gabriel Navar1 January 2008 | American Journal of Physiology-Renal Physiology, Vol. 294, No. 1Dynamic blood pressure load and nephropathy in the ZSF1 (fa/facp) model of type 2 diabetesKaren A. Griffin, Mohammad Abu-Naser, Isam Abu-Amarah, Maria Picken, Geoffrey A. Williamson, and Anil K. Bidani1 November 2007 | American Journal of Physiology-Renal Physiology, Vol. 293, No. 5Cardiovascular Actions of InsulinEndocrine Reviews, Vol. 28, No. 5Assessment of renal autoregulationWilliam A. Cupples, and Branko Braam1 April 2007 | American Journal of Physiology-Renal Physiology, Vol. 292, No. 4Spontaneously reduced blood pressure load in the rat streptozotocin-induced diabetes model: potential pathogenetic relevanceAnil K. Bidani, Maria Picken, Rifat Hacioglu, Geoffrey Williamson, and Karen A. Griffin1 February 2007 | American Journal of Physiology-Renal Physiology, Vol. 292, No. 2Renal autoregulation: new perspectives regarding the protective and regulatory roles of the underlying mechanismsRodger Loutzenhiser, Karen Griffin, Geoffrey Williamson, and Anil Bidani1 May 2006 | American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, Vol. 290, No. 5 More from this issue > Volume 289Issue 2August 2005Pages R305-R306 Copyright & PermissionsCopyright © 2005 the American Physiological Societyhttps://doi.org/10.1152/ajpregu.00297.2005PubMed16014446History Published online 1 August 2005 Published in print 1 August 2005 Metrics